



AVAILABLE PORTFOLIO - MALTA





Apixaban	Micafungin Sodium	Sugammadex Sodium
Cinacalcet HCl	Prucalopride	Sunitinib Malate
Desvenlafaxine Succinate	Rasagiline Tartrate	
Edaravone	Revefenacin	
Lofexidine	Rivaroxaban	

AVAILABLE PORTFOLIO - SPAIN

Adapalene	Guanfacine HCl	Paroxetine HCl
Brimonidine Tartrate	Lamotrigine	Pazopanib
Captopril	Loxapine Base	Pimecrolimus
Clozapine	Loxapine Succinate	Quetiapine Fumarate
Cyclobenzaprine HCl	Mexiletine HCl	Varenicline L-tartrate
Desvenlafaxine Base	Mirtazapine	
Felodipine	Nepafenac [sterile and non sterile]	
Fluvoxamine Maleate	Olopatadine HCl	





UNDER DEVELOPMENT

ACTIVE PHARMACEUTICAL INGREDIENT	REFERENCE PRODUCT	INDICATION	DMF READINESS
 Ivacaftor	Kalydeco® Vertex	Cystic fibrosis	DMF Q4 2024
Opicapone	Ongentys® Bial and Neurocrine Biosciences	“Off” episodes in Parkinson	DMF Q1 2024
Relugolix	Orgovyx®, Myfembree® (US) / RYEQO (EU), Myovant Sciences	Prostate cancer and uterine fibroid bleeding Pain associated with endometriosis	DMF Q2 2024
 Ruxolitinib hemifumarate	Jakavi®, Novartis	Myelofibrosis, polycythemia vera and graft-versus-host-disease	DMF Q2 2024
 Ruxolitinib phosphate	Jakafi®, Novartis	Myelofibrosis, polycythemia vera Graft-versus-host-disease	DMF Q2 2025
Tezacaftor	Symdeko® (US) and Symkevi® (EU) Vertex	Cystic fibrosis	DMF Q1 2027
 Voclosporin	Lupkynis® Aurinia Pharmaceuticals and Otsuka Pharmaceutical	Lupus Nephritis	DMF Q2 2024



UNDER CONSIDERATION

ACTIVE PHARMACEUTICAL INGREDIENT	REFERENCE PRODUCT	INDICATION
Amikacin	Arikayce kit [®] Insmed/PARI Pharma	Mycobacterium avium complex lung disease
Buprenorphine	Brixadi [®] , Butrans [®] and Sublocade [®] Braeburn, Purdue Pharma and Indivior	Opioid use disorder and pain management
Cenobamate	Xcopri [®] (US) and Ontozry [®] (EU) SK Biopharmaceuticals (US) and Angelini (EU)	Partial-onset seizures
 Elexacaftor	Trikafta [®] (US) and Kaftrio [®] (EU) Vertex	Cystic fibrosis
Encorafenib	Braftovi [®] Array (US) and Pierre Fabre (EU)	Unresectable or metastatic melanoma and metastatic colorectal cancer
Levoketoconazole	Recorlev [®] Strongbridge	Endogenous hypercortisolemia in adults with Cushing's syndrome
 Lumacaftor	Orkambi [®] Vertex	Cystic fibrosis
Lorlatinib	Lorbrena [®] (US) and Lorviqua [®] (EU) Pfizer	Metastatic non-small cell lung cancer
Lumateperone tosylate	Caplyta [®] Intra-Cellular Therapies and Bristol Myers Squibb	Schizophrenia and depressive episodes associated with bipolar disorders
Naltrexone	Vivitrol [®] Alkermes	Alcohol and opioid dependence
Naloxone hydrochloride	Kloxxado [®] , Narcan [®] Rextovy [®] , Rivive [®] Hikma, Emergent, Amphastar Pharms, Harm reduction therap	Opioid overdose
Potassium phosphates	Potassium phosphates [®]	Source of phosphorous when oral or enteral replacement is not possible, insufficient or contraindicated
Rimegepant sulphate	Nurtec [®] ODT (US) and Vydura [®] (EU) Pfizer and Biohaven	Migraine
Sodium phosphates	Sodium phosphates [®] , Hospira	Correction or prevention of hypophosphatemia in patients with restricted or no oral intake
Vibegron	Gemtesa [®] Urovant	Overactive bladder
Zanubrutinib	Brukinsa [®] BeiGene	Mantle cell lymphoma, Waldenström's macroglobulinemia, refractory marginal zone mymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma

CHLORHEXIDINE AND OTHER ANTISEPTICS

APIs

API - ANTISEPTICS - AVAILABLE

Chlorhexidine Base		Chlorhexidine Diacetate	CEP
Chlorhexidine Digluconate 20% Solution	CEP	Chlorhexidine Dihydrochloride	CEP
Octenidine Dihydrochloride	DMF		

